P19ARF and RasV12 offer opposing regulation of DHX33 translation to dictate tumor cell fate

Molecular and Cellular Biology

Volumn 33, Issue 8, 2013, Pages 1594-1607

  Zhang, Yandong ^a   Saporita, Anthony J ^a   Weber, Jason D ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARF PROTEIN; DHX33; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P19; RAS PROTEIN; RIBOSOME RNA; RNA POLYMERASE; UNCLASSIFIED DRUG; 1,3 BUTADIENE DERIVATIVE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; CDKN2A PROTEIN, MOUSE; CHROMONE DERIVATIVE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DEAD BOX PROTEIN; DHX33 PROTEIN, HUMAN; DHX33 PROTEIN, MOUSE; DNA DIRECTED RNA POLYMERASE; MDM2 PROTEIN, MOUSE; MESSENGER RNA; MORPHOLINE DERIVATIVE; MTOR PROTEIN, MOUSE; NITRILE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN MDM2; PROTEIN P53; SMALL INTERFERING RNA; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ARTICLE; BIOGENESIS; CELL FATE; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RIBOSOME; RNA TRANSCRIPTION; TUMOR CELL; ANIMAL; C57BL MOUSE; CANCER TRANSPLANTATION; CELL PROLIFERATION; DRUG ANTAGONISM; GENETIC TRANSCRIPTION; GENETICS; HUMAN; METABOLISM; PROTEIN SYNTHESIS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UPREGULATION; XENOGRAFT;

ANIMALS; BUTADIENES; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMONES; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DEAD-BOX RNA HELICASES; HUMANS; MICE; MICE, INBRED C57BL; MORPHOLINES; NEOPLASM TRANSPLANTATION; NITRILES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN BIOSYNTHESIS; PROTO-ONCOGENE PROTEINS C-MDM2; RAS PROTEINS; RIBOSOMES; RNA INTERFERENCE; RNA POLYMERASE I; RNA, MESSENGER; RNA, RIBOSOMAL; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRANSCRIPTION, GENETIC; TRANSPLANTATION, HETEROLOGOUS; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

MLCS; MLOWN;

EID: 84876321639     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.01220-12     Document Type: Article

References (50)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144:646-674.
2. Luo J, Solimini NL, Elledge SJ. 2009. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136:823-837.
3. Drygin D, Rice WG, Grummt I. The RNA polymerase I transcription machinery: an emerging target for the treatment of cancer. Annu. Rev. Pharmacol. Toxicol. 50:131-156.
4. Maggi LB, Jr, Weber JD. 2005. Nucleolar adaptation in human cancer. Cancer Invest. 23:599-608.
5. Montanaro L, Trere D, Derenzini M. 2008. Nucleolus, ribosomes, and cancer. Am. J. Pathol. 173:301-310.
6. White RJ. 2008. RNA polymerases I and III, non-coding RNAs and cancer. Trends Genet. 24:622-629.
7. White RJ. Transcription by RNA polymerase III: more complex than we thought. Nat. Rev. Genet. 12:459-463.
8. Pianese G. 1896. Beitrag zur Histologie und Aetiologie der Carcinoma Histologische und experimentelle Untersuchungen. Beitr. Pathol. Anat. Allgem. Pathol. 142:1-193.
9. Williamson D, Lu YJ, Fang C, Pritchard-Jones K, Shipley J. 2006. Nascent pre-rRNA overexpression correlates with an adverse prognosis in alveolar rhabdomyosarcoma. Genes Chromosomes Cancer 45:839-845.
10. Grummt I. 2003. Life on a planet of its own: regulation of RNA polymerase I transcription in the nucleolus. Genes Dev. 17:1691-1702.
11. Derenzini M, Trere D, Pession A, Govoni M, Sirri V, Chieco P. 2000. Nucleolar size indicates the rapidity of cell proliferation in cancer tissues. J. Pathol. 191:181-186.
12. Derenzini M, Trere D, Pession A, Montanaro L, Sirri V, Ochs RL. 1998. Nucleolar function and size in cancer cells. Am. J. Pathol. 152:1291-1297.
13. Trere D, Ceccarelli C, Montanaro L, Tosti E, Derenzini M. 2004. Nucleolar size and activity are related to pRb and p53 status in human breast cancer. J. Histochem Cytochem. 52:1601-1607.
14. Ayrault O, Andrique L, Fauvin D, Eymin B, Gazzeri S, Seite P. 2006. Human tumor suppressor p14ARF negatively regulates rRNA transcription and inhibits UBF1 transcription factor phosphorylation. Oncogene 25:7577-7586.
15. Learned RM, Learned TK, Haltiner MM, Tjian RT. 1986. Human rRNA transcription is modulated by the coordinate binding of two factors to an upstream control element. Cell 45:847-857.
16. Zhai W, Comai L. 2000. Repression of RNA polymerase I transcription by the tumor suppressor p53. Mol. Cell. Biol. 20:5930-5938.
17. Rubbi CP, Milner J. 2003. Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses. EMBO J. 22:6068-6077.
18. Sherr CJ. 1998. Tumor surveillance via the ARF-p53 pathway. Genes Dev. 12:2984-2991.
19. Yuan X, Zhou Y, Casanova E, Chai M, Kiss E, Grone HJ, Schutz G, Grummt I. 2005. Genetic inactivation of the transcription factor TIF-IA leads to nucleolar disruption, cell cycle arrest, and p53-mediated apoptosis. Mol. Cell 19:77-87.
20. Chedin S, Laferte A, Hoang T, Lafontaine DL, Riva M, Carles C. 2007. Is ribosome synthesis controlled by pol I transcription? Cell Cycle 6:11-15.
21. Laferte A, Favry E, Sentenac A, Riva M, Carles C, Chedin S. 2006. The transcriptional activity of RNA polymerase I is a key determinant for the level of all ribosome components. Genes Dev. 20:2030-2040.
22. Palmero I, Pantoja C, Serrano M. 1998. p19ARF links the tumour suppressor p53 to Ras. Nature 395:125-126.
23. Fernandez-Medarde A, Santos E. Ras in cancer and developmental diseases. Genes Cancer 2:344-358.
24. Ayrault O, Andrique L, Larsen CJ, Seite P. 2004. Human Arf tumor suppressor specifically interacts with chromatin containing the promoter of rRNA genes. Oncogene 23:8097-8104.
25. Downward J. 2003. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 3:11-22.
26. Grandori C, Gomez-Roman N, Felton-Edkins ZA, Ngouenet C, Galloway DA, Eisenman RN, White RJ. 2005. c-Myc binds to human ribosomalDNAand stimulates transcription of rRNA genes by RNA polymerase I. Nat. Cell Biol. 7:311-318.
27. Grewal SS, Li L, Orian A, Eisenman RN, Edgar BA. 2005. Mycdependent regulation of rRNA synthesis during Drosophila development. Nat. Cell Biol. 7:295-302.
28. Shields JM, Pruitt K, McFall A, Shaub A, Der CJ. 2000. Understanding Ras: 'it ain't over 'til it's over'. Trends Cell Biol. 10:147-154.
29. Zhang C, Comai L, Johnson DL. 2005. PTEN represses RNA Polymerase I transcription by disrupting the SL1 complex. Mol. Cell. Biol. 25:6899-6911.
30. Zhang Y, Forys JT, Miceli AP, Gwinn AS, Weber JD. 2011. Identification of DHX33 as a mediator of rRNA synthesis and cell growth. Mol. Cell. Biol. 31:4676-4691.
31. Lessard F, Morin F, Ivanchuk S, Langlois F, Stefanovsky V, Rutka J, Moss T. The ARF tumor suppressor controls ribosome biogenesis by regulating the RNA polymerase I transcription factor TTF-I. Mol. Cell 38:539-550.
32. Weber JD, Jeffers JR, Rehg JE, Randle DH, Lozano G, Roussel MF, Sherr CJ, Zambetti GP. 2000. p53-independent functions of the p19ARF tumor suppressor. Genes Dev. 14:2358-2365.
33. Itahana K, Bhat KP, Jin A, Itahana Y, Hawke D, Kobayashi R, Zhang Y. 2003. Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. Mol. Cell 12:1151-1164.
34. Zhang Y, Xiong Y, Yarbrough WG. 1998. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92:725-734.
35. Basu TN, Gutmann DH, Fletcher JA, Glover TW, Collins FS, Downward J. 1992. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 356:713-715.
36. Dasgupta B, Yi Y, Chen DY, Weber JD, Gutmann DH. 2005. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer research. 65:2755-2760.
37. Johannessen CM, Reczek EE, James MF, Brems H, Legius E, Cichowski K. 2005. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc. Natl. Acad. Sci. U. S. A. 102:8573-8578.
38. Stefanovsky V, Langlois F, Gagnon-Kugler T, Rothblum LI, Moss T. 2006. Growth factor signaling regulates elongation of RNA polymerase I transcription in mammals via UBF phosphorylation and r-chromatin remodeling. Mol. Cell 21:629-639.
39. Stefanovsky VY, Pelletier G, Hannan R, Gagnon-Kugler T, Rothblum LI, Moss T. 2001. An immediate response of ribosomal transcription to growth factor stimulation in mammals is mediated by ERK phosphorylation of UBF. Mol. Cell 8:1063-1073.
40. Zhao J, Yuan X, Frodin M, Grummt I. 2003. ERK-dependent phosphorylation of the transcription initiation factor TIF-IA is required for RNA polymerase I transcription and cell growth. Mol. Cell 11:405-413.
41. Voit R, Grummt I. 2001. Phosphorylation of UBF at serine 388 is required for interaction with RNA polymerase I and activation of rDNA transcription. Proc. Natl. Acad. Sci. U. S. A. 98:13631-13636.
42. Voit R, Hoffmann M, Grummt I. 1999. Phosphorylation by G1-specific cdk-cyclin complexes activates the nucleolar transcription factor UBF. EMBO J. 18:1891-1899.
43. Hannan KM, Brandenburger Y, Jenkins A, Sharkey K, Cavanaugh A, Rothblum L, Moss T, Poortinga G, McArthur GA, Pearson RB, Hannan RD. 2003. mTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxyterminal activation domain of the nucleolar transcription factor UBF. Mol. Cell. Biol. 23:8862-8877.
44. Mayer C, Zhao J, Yuan X, Grummt I. 2004. mTOR-dependent activation of the transcription factor TIF-IA links rRNA synthesis to nutrient availability. Genes Dev. 18:423-434.
45. Kawagishi H, Nakamura H, Maruyama M, Mizutani S, Sugimoto K, Takagi M, Sugimoto M. ARF suppresses tumor angiogenesis through translational control of VEGFA mRNA. Cancer Res. 70:4749-4758.
46. Ghoshal K, Jacob ST. 1997. An alternative molecular mechanism of action of 5-fluorouracil, a potent anticancer drug. Biochem. Pharmacol. 53:1569-1575.
47. Jordan P, Carmo-Fonseca M. 1998. Cisplatin inhibits synthesis of rRNA in vivo. Nucleic Acids Res. 26:2831-2836.
48. Pondarre C, Strumberg D, Fujimori A, Torres-Leon R, Pommier Y. 1997. In vivo sequencing of camptothecin-induced topoisomerase I cleavage sites in human colon carcinoma cells. Nucleic Acids Res. 25:4111-4116.
49. Drygin D, Siddiqui-Jain A, O'Brien S, Schwaebe M, Lin A, Bliesath J, Ho CB, Proffitt C, Trent K, Whitten JP, Lim JK, Von Hoff D, Anderes K, Rice WG. 2009. Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis. Cancer Res. 69:7653-7661.
50. Drygin D, Lin A, Bliesath J, Ho CB, O'Brien SE, Proffitt C, Omori M, Haddach M, Schwaebe MK, Siddiqui-Jain A, Streiner N, Quin JE, Sanij E, Bywater MJ, Hannan RD, Ryckman D, Anderes K, Rice WG. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits rRNA synthesis and solid tumor growth. Cancer Res. 71:1418-1430.